US Stock MarketDetailed Quotes

FULC Fulcrum Therapeutics

Watchlist
  • 3.690
  • -0.020-0.54%
Close Feb 14 16:00 ET
  • 3.690
  • 0.0000.00%
Post 16:01 ET
199.03MMarket Cap-12.72P/E (TTM)

About Fulcrum Therapeutics Company

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Company Profile

SymbolFULC
Company NameFulcrum Therapeutics
Listing DateJul 18, 2019
Issue Price16.00
Founded2015
CEOMr. Alex C. Sapir
MarketNASDAQ
Employees76
Fiscal Year Ends12-31
Address26 Landsdowne Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-651-8851

Company Executives

  • Name
  • Position
  • Salary
  • Alex C. Sapir
  • Director, President and Chief Executive Officer
  • 6.99M
  • Curtis G. Oltmans
  • Chief Legal Officer
  • 2.32M
  • Dr. Patrick Taylor Horn, M.D.,PhD.
  • Chief Medical Officer
  • --
  • Alan A. Musso
  • Chief Financial Officer and Treasurer
  • 1.88M
  • Gregory Tourangeau
  • Vice President, Finance, Controller and Principal Accounting Officer
  • --
  • Melvin H. Hayes, III
  • Executive Vice President, Patient Experience
  • 2.19M
  • Kate Haviland
  • Chairman of the Board
  • 157.90K
  • Dr. Robert J. Gould, PhD
  • Director
  • 424.50K
  • Sonja Banks
  • Independent Director
  • 121.40K
  • Rachel King
  • Independent Director
  • --
  • Dr. Alan Ezekowitz, D.Phil.,MB.Ch.B.
  • Independent Director
  • 131.40K
  • Colin Hill
  • Independent Director
  • --
  • Katina Dorton, J.D.,M.B.A.
  • Independent Director
  • 136.40K
  • James A. Geraghty
  • Independent Director
  • 131.90K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More